Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in CF Children 6-11 Years (F/MF)
NCT04353817Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of elexacaftor + tezacaftor + ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Jun 2020; status: completed.
02
Drugs
elexacaftor + tezacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04353817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04353817.